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Abstract
Background: CD8+ T cells may play an important role in protecting against HIV. However, the changes of CD8+ T
cell subsets during early period of ART have not been fully studied.
Methods: Twenty-one asymptomatic treatment-naive HIV-infected patients with CD4 T+ cells less than 350 cells/μl
were enrolled in the study. Naïve, central memory(CM), effective memory(EM) and terminally differentiated effector
(EMRA) CD8+ cell subsets and their activation and proliferation subsets were evaluated in blood samples collected
at base line, and week 2, 4, 8 and 12 of ART.
Results: The total CD8+ T cells declined and the Naïve and CM subsets had a tendency of increase. Activation
levels of all CD8+ T cell subsets except EMRA subset decreased after ART. However, proliferation levels of total
CD8+ T cells, EMRA, EM and CM subsets increased at the first 4 weeks of ART, then decreased. Proliferation level of
the naïve cells decreased after ART.
Conclusion: The changes of CD8+ T cell subsets during initial ART are complex. Our results display a complete
phenotypical picture of CD8+ cell subsets during initial ART and provide insights for understanding of immune
status during ART.
Background
CD8+ T cells play an important role in protection against
intracellular pathogens. Eliminating CD8+ T lymphocytes
from monkeys during chronic SIV infection resulted in a
rapid and marked increase in viremia, which was again
suppressed coincident with the reappearance of SIV-spe-
cific CD8+ T cells. Antiviral CD8+ T cells controlled the
acute viremic phase of the infection, resulting in the
establishment of the viral set point [1-3].
Many studies [4-6] evaluated the changes of CD4+ cell
subsets during antiretroviral treatment (ART). However,
the changes of CD8+ T cell subsets in early period of
ART have not been fully studied yet.
Here, in our study, we investigated the characteristics
of naive (CD45RA +CCR7+), central memory (CM)
(CD45RA - CCR7+), effector memory (EM) (CD45RA-
CCR7-), and terminally differentiated effector (EMRA)
(CD45RA+ CCR7-) cell subsets [7,8], as well as activa-
tion and proliferation levels of each subset, during initial
ART in Chinese patients. Our results demonstrated that
most of the CD8+ cell subsets decrease during initial
ART, while Naïve and CM subsets have a tendency of
increase, which may reflect the immune reconstitution
of CD8+ T cells.
Results
Baseline demographic and clinical characteristics of the
subjects
A total of 21 HIV/AIDS patients were enrolled from
Beijing You’an Hospital, Capital Medical University. At
baseline, the average age of subjects was 36.8 ±12.1
years (range, 23-64 years). The median plasma viral load
of subjects was 148,141 copies/ml (interquartile range
1,294-1,157,417 copies/mL), and the median CD4+ T
cell count was 230 cells/μl (interquartile range 46-349
cells/μl). The median CD8+ T cell count was 1053 cells/
μl (interquartile range 382-1675). And most of the sub-
jects were men who have sex with men (MSM).
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subsets
The gating strategy of CD8+ T cell populations was
s h o w ni nf i g u r e1 .L o n g i t u d i n a la n a l y s e so fC D 8 +T
cells, naïve, CM, EM and EMRA subsets in patients
with asymptomatic chronic HIV infection after ART
w e r es h o w ni nf i g u r e2 .T h em a j o rc o m p o n e n t so f
CD8+ cells were EM and EMRA subsets, which
accounted for over 80 percent. Naïve and CM subsets
only accounted for less than 20 percent.
The median of CD8+ T cells decreased from 1053 to
904 cells/μl after 12 weeks of ART. Among the four
subsets of CD8+ cells, CD8+ EM and CD8+ EMRA sub-
sets had the same change pattern with CD8+ T cells.
The median of CD8+ EM subset decreased significantly
from 627 to 520 cells/μl. Similarly, the median of CD8+
EMRA subset decreased significantly from 325 to 272
cells/μl.
The median of CD8+ naïve cells at baseline, week 2, 4,
8 and 12 was 79, 91, 99, 98, 102 cells/μl respectively.
There were no significant differences among them. The
median of CD8+ CM subset kept slowly rising, from 21
cells/μl at baseline to 43 cells/μl at week 12 after ART.
Activation of CD8+ cell subsets
We next investigated the effect of ART on T cell activa-
tion. HIV-infected individuals had higher T-cell activa-
tion in the blood as indicated by expression of HLA-DR
and CD38 [9]. Given the limited experimental condi-
tions, we did not stain CD38 with HLA-DR simulta-
neously. At baseline the median proportion of activated
CD8+ T lymphocytes (CD38+) exceeded 80% and gra-
dually declined over 12 weeks, reaching 73.77% (73.77 ±
9.14) at the last follow up visit. Activation of CD8+ EM
subsets decreased in a similar way, from 83.53% at base-
line to 72.87% at week 12. The median of activation of
CD8+ naïve cell subset was 62.997% at baseline. It fluc-
tuated between 49.09% and 65.79%, reaching to 63.32%
at week 12.
The median of percentage of CD38+ CD8+ CM subset
was 57.81%, 55.63%, 52.82%, 54.49% and 50.18% respec-
tively at the 5 times of follow up visits, fluctuating
between 50% and 58%. The median of CD8+ EMRA
subset was 84.43%, 86.11%, 83.64%, 85.22% and 83.90%
respectively at the 5 times of follow up visits, staying at
a high level. Activation levels of the two subsets had no
significant changes after ART.
With respect to HLA-DR expression on CD8+ lym-
phocytes, there was also a high percentage of expression
at base line. The percentage of HLA-DR expression
decreased from 76.91% at baseline to 71.26 at week 12
after ART, which has the similar change pattern to that
of CD38 expression.
The median of HLA-DR expression on CD8+ naïve
cell subset declined from 9.39% at baseline to 7.24% at
week 12 after ART. For CD8+ CM subset, the median
percentage of HLA-DR expression declined from 65.91%
at baseline to 51.43% at week 12. The median percen-
t a g e so fC D 8 +E Ma n dE M R As u b s e t sw e r eb o t hi na
high level around 80%. There were no significant
changes in activation of CD8+ EM and EMRA subsets
as indicated by HLA-DR.
Proliferation of CD8+ cell subsets
Proliferating subsets are calculated by measurement
of Ki67 expression. The median of percentage of
Ki67+CD8+ T cells elevated slightly at the first 4 weeks
of ART, then decreased gradually. Their values at the 5
times of follow up visits were 4.85%, 7.27%, 6.85%,
5.73% and 4.27% respectively.
The median of proliferation of CD8+ naïve subset was
1.29%, 1.47%, 1.33%, 0.83% and 0.85% respectively at the
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Figure 1 The gating strategy of CD8+ T cell populations from a single representative subject. Lymphocytes were gated first. Then CD8+
cells were gated. Central memory (CM; CD45RA-CCR7+), naive (CD45RA + CCR7+), effector memory (EM; CD45RA-CCR7-), and terminally
differentiated effector (EMRA; CD45RA + CCR7-) subsets were gated based on gated CD8+ cells.
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Page 2 of 75 times of follow up visits. And the median of prolifera-
tion of CD8+ CM subset was 7.47%, 8.05%, 8.52%,
5.41% and 4.40% respectively. Both of the two subsets
had the trend of decline.
Ki67 expression on CD8+ EM cells had no signifi-
cantly change after ART, fluctuating between 5.60% and
9.65%. For CD8+ EMRA cells, percentage of Ki67 posi-
tive cells elevated after ART, reaching to peak of 4.09%
at week 8, then decreased to 2.74% at week 12.
The changes of mean fluorescence index (MFI) of
CD38 and Ki67 on CD8+ cell subsets have the same
pattern with those of percentages (data not shown).
Discussion
It has been reported previously that changes in the levels of
T cell subsets occurred after a long-term of ART, showing
a biphasic increase in CD4+ T cells and a trend of decrease
in CD8+ T cells [4-6]. However, little is known about the
change of CD8+ cell subsets during early period of ART.
In this study we investigated the dynamic changes not only
in CD8+ cell subsets, but also in their activation and prolif-
eration subsets in Chinese HIV/AIDS patients during early
period of ART, particularly in MSM population.
The number of CD 8+ T cells decrease after long-
term of ART [10,11]. Since their follow-up intervals are
too long, the early dynamic of CD8+ T cells can not be
presented completely. Here, our results displayed a com-
plete phenotypical picture of CD8+ cell subsets during
initial ART. The total CD8+ T cells had a tendency of
decrease (see figure 2).
Of the 4 subsets we studied, EMRA and EM subsets
declined in consistent with total CD8+ T cells, while the
naïve and CM subsets had a tendency of increase during
the first 3 months of ART (see figure 2). However, most
of the changes had no significant differences. From the
results we can see that the declines of CD8+ T cells are
mainly composed of EMRA and EM subsets, which may
play important roles in direct killing of target cells. The
decrease of EMRA and EM subsets may result from the
migration of these cells from blood to lymph tissues
[12]. Another reason may be the decline of HIV anti-
gens after ART [13,14].
During progressive HIV infection, naive T cells are
preferentially targeted, causing a marked decrease in
their proportion [15,16]. The process of immune recov-
ery in HAART-treated adults induces a slow sustained
increase of naive lymphocytes [13,17]. The memory sub-
set derives from the naive cells by a post-thymic
maturation process. Our results showed that the
naïve and CM subsets have a tendency of increase.
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Figure 2 Percentage changes in absolute CD8+ T cells and each phenotypic subset during initial ART (weeks). (A-E) Percentage changes
of CD8+ T cells, CD8 CM, CD8 EM and CD8 EMRA subsets respectively. (F) Mean percentage changes of CD8+ T cells, CD8 CM, CD8 EM and
CD8 EMRA subsets.
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Page 3 of 7The increase of naïve and CM subsets may originate
from non-HIV specific CD8 cells, as was previous
reported [18] that CD8+ memory cells increased follow-
ing HAART were not considered as HIV-specific T
cells.
Activation of T cells is an important pathogenetic
event in HIV infection, which can be indicated by the
elevated expression of different antigens like CD38 and
HLA-DR on the surface of T lymphocytes [9]. CD38
level is a strongest predictive marker of HIV disease
progression [19,20] and may even predict antiretroviral
therapy (ART) treatment failure [21,22]. Several studies
[23-25] showed activated CD8+ T cells decreased after
ART. But they did not reveal the change of activated
CD8+ cell subsets. Both CD38 and HLA-DR expression
on CD8+ cell subsets decreased after ART in our study.
However, the magnitude of decrease is not remarkable
in some subsets of CD8+ T cells, especially EMRA sub-
set (see figure 3 and 4). One explanation is that the
plasma HIV viral loads are still above lower detection
limit (LDL) in most patients after 3 month of ART (data
not shown). Another reason is the potential exist of var-
ious opportunistic viral and bacterial infections.
T-cell proliferation based on Ki67 expression is corre-
lated generally with those obtained using direct
techniques [26,27], such as [2H] glucose incorporation.
There are some differences on the changes of percen-
tage of ki67+ CD8+ T cells. One report showed that the
percentages of CD8+Ki67+ cells increased during ART
[28], and the subset was maintained at a high percentage
until 18 weeks post ART. Another report [29] demon-
strated a decline of percentages of CD8+Ki67+ cells.
Our results showed that the percentages of Ki67+CD8+
cells as well as EM and EMRA subsets increased, while
those of naïve and CM subsets decreased (see figure 5).
The differences may come from sources of patients,
stage of the disease and duration of treatment time.
In conclusion, the changes of CD8+ T cell subsets
during initial ART are complex. Almost all of the CD8+
cell subsets declined in activation levels during initial
ART. However, the trends of proliferation levels in dif-
ferent CD8+ subsets were inconsistent. Further studies
are needed to perform on a large scale and general
population.
Materials and methods
Participants and study
Twenty-one HIV-1-infected treatment-naïve patients
were randomly enrolled from HIV/AIDS clinic of Beijing
You’an Hospital, with CD4+ T cell counts at less than
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Figure 3 Percentage changes in CD38 expressed CD8+ T cells and each phenotypic subset during initial ART (weeks). (A-E) Percentage
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Page 5 of 7350 cells/ul and no opportunistic infections within the
previous three months. Exclusion criteria included preg-
nancy, active tuberculosis, or serious liver/renal dysfunc-
tion. All individuals were treated with ART, which
included 3TC + d4T (or AZT) + NVP. The study was
approved by the Beijing You’an Hospital Research Ethics
Committee, and written informed consent was obtained
from each subject.
Collection of Blood Samples
Fasting venous blood samples were collected at 8-9 in
the morning in EDTA-containing tubes at baseline, 2, 4,
8 and 12 weeks of treatment. Peripheral blood mono-
nuclear cells (PBMCs) were isolated by Ficoll-Hypaque
density gradient centrifugation. Activation and prolifera-
tion markers were detected immediately after isolation.
Flow cytometric analysis
The monoclonal antibodies (mAbs) of CD8+-PerCP,
CCR7-FITC, HLA-DR-PE and CD38-PE were purchased
from BD Bioscience (San Diego, CA, USA). Anti-
CD45RA-APC and anti-Ki67-PE was purchased from
eBioscience (San Diego, CA, USA).
Levels of immune activation were examined through
CD38 and HLA-DR expressions on different subsets of
CD8+ T lymphocytes. Freshly isolated PBMCs were
stained with ant-CD8-PerCP, anti-CD45RA-APC, anti-
CCR7-FITC and anti-CD38-PE or anti-HLA-DR-PE or
the corresponding IgG1-PE isotype control according to
manufacturer’s instructions.
Cell proliferation was studied by measuring expression
of the Ki-67 antigen. Freshly isolated PBMCs were incu-
bated with anti-CD8-PerCP, anti-CD45RA-APC, anti-
CCR7-FITC at 4°C for 30 min according to manufac-
ture’s instructions. After washing with phosphate-buf-
fered saline (PBS), permeabilization was performed by
incubating cells with Cytofix/Cytoperm (BD Pharmigen,
San Diegio, CA) at 4°C for 20 min. Cells were stained
intracellulary with anti-Ki67-PE or the corresponding
isotype control anti-IgG1-PE at room temperature for 30
min. After washing with PBS, Four-color flow cytometric
analyses were then performed using FACSCalibur and
CELLQuest software (Becton Dickinson, San Jose, CA).
Assays for CD4+ and CD8+ T cell counts and Plasma HIV-
1 RNA
After whole-blood lysis (FACSlysing Solution, Becton
Dickinson San Diego, CA, USA), T lymphocyte counts
were determined by three-color flow cytometry using
CD3-APC, CD4-FITC and CD8+-PE monoclonal anti-
body (BD Bioscience San Diego, CA, USA). The analysis
was performed on a BD FACSCount flow cytometer in
accordance with Chinese Center for Disease Control
and Prevention (CDC) guidelines.
Plasma viral load were measured by the Amplicor
HIV-1 monitor ultrasensitive Method (Roche, Germany),
with a detection limit of 40 copies/ml of plasma.
Statistical analysis
Data analysis was performed with SPSS 11.5 for Win-
dows software (SPSS Inc, Chicago, IL). Statistical signifi-
cance within groups was analyzed with Kruskal-Wallis
Test; statistical significance between groups was ana-
lyzed with the Mann-Whitney U test. P < 0.05 is consid-
ered statistically significant.
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